DNAY

Codex DNA, Inc. (DNAY) | Rumor.io

Codex DNA

DNAY

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about DNAY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 9

Codex DNA's benchtop DNA printer is executing on a roadmap to reduce limitations over time, with a recent collaboration with PFE on mRNA in 4Q21.
The company has a $50m cash position and has launched a high-throughput system, with potential milestones of up to $30m over the next 12-18 months.
KeyCorp has lowered its price target for Telesis Bio (DNAY) to $5 from $8, while maintaining an Overweight rating.

Generated by AI

Sentiment

Of the messages about DNAY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	0% -100
Bearish	—	—	—	100% new

Bullish· Jun 22

$DNAY has a strong potential for further growth due to its prime setup and favorable conditions.
The company's founding by J. Craig Venter, the "King of Genomics," adds to its value and makes it a worthwhile investment.
$DNAY is likely to experience increased volatility and potentially reach new highs, making it a promising trade for bulls.

Bearish· Mar 24

$DNAY has dropped to new 52 week lows, with the author questioning when the bottom will be reached and expecting further decline.
The author believes that a large investor is manipulating the stock price downward, causing significant losses.
The company's financial position is seen as fragile, with concerns about dilution and a potential cash shortage before the end of the year.

Generated by AI

Topics

Of the messages about DNAY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Announcements· Jan 10

Codex DNA, Inc. (DNAY) announced a strategic collaboration and licensing agreement with Pfizer to access and further develop Codex DNA's novel EDS technology for potential application in mRNA-based vaccines and biotherapies.
Under the agreement, Codex DNA will receive an upfront payment of $8 million, with potential for up to $180 million in sales milestones and royalty payments if its technology results in marketable products for Pfizer.
The collaboration aims to support Pfizer's research and development of mRNA-based vaccines and biotherapies, with Codex DNA's technology expected to enhance the efficiency and scalability of Pfizer's product development process.

Technical Analysis· Dec 31

A cup and handle pattern is forming in DNAY, with resistance at $11 and the bottom of the handle at $10, potentially leading to a price increase above $12.50.
DNAY has shown a pin bar inside day and held up, with a key level for a breakout at $11.12 and above $12.20, indicating potential for further price growth.
DNAY is in an uptrend, with a MACD Histogram crossing above the signal line, and has been bouncing off support, suggesting it may push through resistance and continue its upward trend.

Generated by AI

Community

Of the messages about DNAY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	100%
Newcomers	—	—	—	0%

Also Discussed

Investors talking about DNAY also mention

#	Name	Attention
1	Nutriband Inc.NTRB	0%0
2	FATH - Fathom Digital Manufacturing Corporation	——
3	Immix Biopharma, Inc.IMMX	0.03%+0.03
4	GRTX - Galera Therapeutics, Inc.	——
5	Aptorum Group Ltd.APM	0%new
6	HeartCore Enterprises, Inc.HTCR	0%0
7	TBIO - Telesis Bio, Inc.	——
8	Biofrontera Inc.BFRI	0%0
9	CYAD - Celyad Oncology S.A.	——
10	Aridis Pharmaceuticals Inc.ARDS	0%new

Codex DNA, Inc.

Location

Social

What share of all stock conversation is about DNAY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 9

Codex DNA's benchtop DNA printer is executing on a roadmap to reduce limitations over time, with a recent collaboration with PFE on mRNA in 4Q21.
The company has a $50m cash position and has launched a high-throughput system, with potential milestones of up to $30m over the next 12-18 months.
KeyCorp has lowered its price target for Telesis Bio (DNAY) to $5 from $8, while maintaining an Overweight rating.

Generated by AI

Sentiment

Of the messages about DNAY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	0% -100
Bearish	—	—	—	100% new

Bullish· Jun 22

$DNAY has a strong potential for further growth due to its prime setup and favorable conditions.
The company's founding by J. Craig Venter, the "King of Genomics," adds to its value and makes it a worthwhile investment.
$DNAY is likely to experience increased volatility and potentially reach new highs, making it a promising trade for bulls.

Bearish· Mar 24

$DNAY has dropped to new 52 week lows, with the author questioning when the bottom will be reached and expecting further decline.
The author believes that a large investor is manipulating the stock price downward, causing significant losses.
The company's financial position is seen as fragile, with concerns about dilution and a potential cash shortage before the end of the year.

Generated by AI

Topics

Of the messages about DNAY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Announcements· Jan 10

Codex DNA, Inc. (DNAY) announced a strategic collaboration and licensing agreement with Pfizer to access and further develop Codex DNA's novel EDS technology for potential application in mRNA-based vaccines and biotherapies.
Under the agreement, Codex DNA will receive an upfront payment of $8 million, with potential for up to $180 million in sales milestones and royalty payments if its technology results in marketable products for Pfizer.
The collaboration aims to support Pfizer's research and development of mRNA-based vaccines and biotherapies, with Codex DNA's technology expected to enhance the efficiency and scalability of Pfizer's product development process.

Technical Analysis· Dec 31

A cup and handle pattern is forming in DNAY, with resistance at $11 and the bottom of the handle at $10, potentially leading to a price increase above $12.50.
DNAY has shown a pin bar inside day and held up, with a key level for a breakout at $11.12 and above $12.20, indicating potential for further price growth.
DNAY is in an uptrend, with a MACD Histogram crossing above the signal line, and has been bouncing off support, suggesting it may push through resistance and continue its upward trend.

Generated by AI

Community

Of the messages about DNAY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	100%
Newcomers	—	—	—	0%

Codex DNA

Social

Nov 9

Sentiment

Bullish· Jun 22

Bearish· Mar 24

Topics

Announcements· Jan 10

Technical Analysis· Dec 31

Community

Also Discussed

Codex DNA, Inc.

Company Information

Location

Also Discussed

Social

Nov 9

Sentiment

Bullish· Jun 22

Bearish· Mar 24

Topics

Announcements· Jan 10

Technical Analysis· Dec 31

Community